David A. Bluemke

Jan 16, 2025 | heart.bmj.com | Avan Suinesiaputra |Kathleen McGuire Gilbert |David A. Bluemke |Charlene Mauger

Risk FactorsCohort StudiesMagnetic Resonance ImagingData availability statementData may be obtained from a third party and are not publicly available. The MESA CMR images and their clinical and demographic data used in this study are available on request to the MESA Coordinating Centre at[https://www.mesa-nhlbi.org]. The UK Biobank CMR images and their clinical and demographic data used in this study are available on request to the UK Biobank at [https://www.ukbiobank.ac.uk].

Sep 12, 2024 | onlinelibrary.wiley.com | Tess Peterson |Joao Lima |Sanjiv Shah |David A. Bluemke

Introduction Heart failure (HF) diagnosis is largely limited to symptomatic stages,1 before which preclinical alterations in cardiac structure often occur.2-4 These diagnostic limitations are highly problematic due to the high prevalence of asymptomatic subclinical disease5, 6 and high mortality after incident HF diagnosis.7 Heterogeneity in HF pathophysiology contributes to the challenge of early diagnosis and treatment.

Sep 19, 2023 | pubs.rsna.org | David A. Bluemke

See also the article by Nakahara et al in this issue. The development of messenger RNA (mRNA) COVID-19 vaccines is a remarkable biotech story. While traditional vaccines took 5-10 years to develop, the COVID-19 vaccines took less than a year. By comparison, the fastest conventional vaccine previously developed was the mumps vaccine, on a timescale of 4 years.